Form 4: Cullinan Therapeutics' Chief Medical Officer Sells Shares to Cover Tax Obligations

Jeffrey Alan Jones, Chief Medical Officer of Cullinan Therapeutics, sold 4,632 shares of common stock on December 18, 2024, to cover personal income tax obligations upon the vesting of restricted stock units.

Summary

• On December 18, 2024, Jeffrey Alan Jones, the Chief Medical Officer of Cullinan Therapeutics, Inc. (CGEM), sold 4,632 shares of the company's common stock.
• The sale was executed at a price of $11.41 per share.
• This transaction was conducted to cover personal income tax obligations arising from the vesting of restricted stock units.
• Following the sale, Jones directly owns 114,059 shares of Cullinan Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations, which is a common practice among company executives.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. However, sales to cover tax obligations are common and don't necessarily indicate a negative outlook.

Stakeholder Impact

• The sale could have a minor, temporary impact on shareholders due to the increased supply of shares in the market.
• The impact on employees, customers, suppliers, and creditors is expected to be negligible.

Key Dates